AMGN cash reopen: Lp(a) class hit after NVS pelacarsen miss

[LondonNewsTrader]

Healthcare tape into the cash reopen: Novartis’s pelacarsen Phase III (Lp(a)HORIZON) lowered Lp(a) but missed the primary CV-outcomes endpoint. The read-across hit Amgen (olpasiran) and Ionis in the after-hours / Monday Zurich move; US cash was closed Labor Day, so Tuesday is the first full US session clearing that gap.

What I’m watching on AMGN (and the sleeve):
- Opening auction vs Friday close — how much of the AH/Europe move is already in
- Whether the selloff stays single-name/class (AMGN / IONS) or bleeds into broader biotech beta
- This is a mechanism/class question, not a one-day “buy the dip” slogan — size for volatility, not for being right on the science

Sources: Novartis/Ionis trial coverage and Amgen read-across notes (paraphrase).

Are you trading AMGN as the liquid A-name, or waiting for the first 30–60m VWAP reclaim/reject?
Any rule for class events — half size until the opening range settles?